<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>CLINICAL FEATURES OF THE COURSE OF GOUT</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">K.R.</mods:namePart><mods:namePart type="family">Abdushukurova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Kazimov Sukhrob</mods:namePart><mods:namePart type="family">Bohodirovich</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>To identify the frequency and nature of clinical and laboratory signs of metabolicnbsp;syndrome in patients with gout. 49 male gout patients were examined in thenbsp;rheumatology department. Thus, the acute variant of gouty arthritis was noted innbsp;42.9%, prolonged – in 22.4% and chronic – in 34.7% of patients. Tofuses were foundnbsp;in 26.5% of patients. Very often, the comorbid course of gout and metabolic syndromenbsp;is due to a hereditary predisposition, the methods of prevention of which in gout cannbsp;be the preservation of motor activity, dietary correction of body weight, as well asnbsp;timely basic treatment.nbsp;</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-01-11</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Research Science and Innovation house</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>